Patents Assigned to DeveloGen Aktiengesellschaft
-
Publication number: 20130231283Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.Type: ApplicationFiled: February 1, 2013Publication date: September 5, 2013Applicant: DeveloGen AktiengesellschaftInventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
-
Publication number: 20130150293Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.Type: ApplicationFiled: February 15, 2013Publication date: June 13, 2013Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventor: DEVELOGEN AKTIENGESELLSCHAFT
-
Patent number: 8399408Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a neurturin protein product.Type: GrantFiled: February 15, 2011Date of Patent: March 19, 2013Assignee: DeveloGen AktiengesellschaftInventors: Matthias Austen, Ulrike Burk
-
Publication number: 20130053313Abstract: The present invention relates to formulations with protein growth factors, particularly neurturin as active ingredients and low molecular weight polyanionic excipients having increased bioavailability.Type: ApplicationFiled: August 27, 2012Publication date: February 28, 2013Applicant: DeveloGen AktiengesellschaftInventors: Friedrich Harder, Matthias Austen
-
Publication number: 20120045452Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing a pancreatic malfunction, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing a pancreatic malfunction.Type: ApplicationFiled: September 26, 2011Publication date: February 23, 2012Applicant: DeveloGen Aktiengesellschaft fuer Entwicklungsbiologische ForschungInventors: Arnd Steuernagel, Karsten Eulenberg, Günter Brönner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jäkel, Christoph Meyer
-
Publication number: 20120045451Abstract: This invention relates to the use of nucleic acid sequences of the MAP kinase-interacting kinase (Mnk) gene family and amino acid sequences encoded thereby, and to using these sequences or effectors of Mnk nucleic acids or polypeptides, particularly Mnk kinase inhibitors and activators, in the diagnosis and treatment of diseases and disorders related to body-weight regulation and thermogenesis. One aspect of the disclosure encompasses methods of identifying an animal or human having an elevated probability of having or developing obesity, the method comprising: (a) obtaining a biological sample from an animal or human subject; and (b) determining from the biological sample whether the animal or human subject has a genetic variant of an Mnk2 and/or Mnk1 gene or a homolog thereof, or an expression product of said Mnk2 and/or Mnk1 gene or homolog thereof, wherein said genetic variant is associated with an elevated probability of having or developing obesity.Type: ApplicationFiled: September 26, 2011Publication date: February 23, 2012Applicant: DeveloGen Aktiengesellschaft fuer Entwicklungsbiologische ForschungInventors: Arnd Steuernagel, Karsten Eulenberg, Guenter Broenner, Thomas Ciossek, Bettina Rudolph, Dorothea Rudolph, Funmi Belgore, Stefan Jakel, Christoph Meyer
-
Publication number: 20110003741Abstract: The present invention relates to neurturin protein products conjugated to polyols and to pharmaceutical compositions comprising neurturin conjugates as active ingredients, preferably PEGylated neurturin conjugates or variants thereof, having increased bioavailability.Type: ApplicationFiled: May 5, 2010Publication date: January 6, 2011Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventors: Matthias Austen, Marcus Geese, Rainer Mussmann, Friedrich Harder, Thomas Siegmund, Martin Schneider
-
Publication number: 20100143341Abstract: The present invention relates to novel pharmaceutical compositions of general formula (I) comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.Type: ApplicationFiled: June 21, 2006Publication date: June 10, 2010Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventors: Steven Taylor, Stephen Murfin, Thomas Stephen Coulter, Stefan Jakel, Babette Aicher, Arndt-Rene Kelter, Joachim Kraemer, Christian Kirchhoff, Andreas Scheel, Julian Woelcke
-
Publication number: 20100105708Abstract: The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.Type: ApplicationFiled: July 10, 2007Publication date: April 29, 2010Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventors: Stefan Jäkel, Tanja Reuter, Stephen Murfin, Thomas Stephen Coulter, Steven Taylor
-
Publication number: 20100056548Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.Type: ApplicationFiled: April 10, 2007Publication date: March 4, 2010Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventors: Babette Aicher, Thomas Stephen Coulter, Stefan Jaekel, Arndt-René Kelter, Stephen Murfin, Tanja Reuter, Steven Taylor
-
Publication number: 20090298771Abstract: This invention relates to the use of secreted SF01-SF13 proteins, to the use of polynucleotides encoding these, and to the use of effectors/modulators thereof in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes mellitus), obesity and/or metabolic syndrome and to the use in regeneration of tissues such as pancreatic tissues and others.Type: ApplicationFiled: May 8, 2009Publication date: December 3, 2009Applicant: DeveloGen AktiengesellschaftInventor: Daria Onichtchouk
-
Publication number: 20090170095Abstract: The present invention discloses Mnk homologous proteins regulating the energy homeostasis, the metabolism of triglycerides, and/or is contributing to membrane stability and/or function of organelles, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation and thermogenesis, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as eating disorder, cachexia, diabetes mellitus, hypertension, coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, and sleep apnea, and disorders related to ROS defence, such as diabetes mellitus, neurodegenerative disorders, and cancer, e.g. cancers of the reproductive organs, and others.Type: ApplicationFiled: July 16, 2008Publication date: July 2, 2009Applicant: DeveloGen Aktiengesellschaft fuer Entwicklungsbiologische ForschungInventors: Arnd Steuernagel, Karsten Eulenberg, Gunter Broenner, Thomas Clossek, Bettina Rudoplh, Dorothea Rudolph, Funmi Belgore, Stefan Jakel, Christoph Meyer
-
Patent number: 7404952Abstract: The present invention discloses three novel proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides of the invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as adipositas, eating disorders, wasting syndromes (cachexia), pancreatic dysfunctions (such as diabetes mellitus), hypertension, pancreatic dysfunctions, arteriosclerosis, coronary artery disease (CAD), coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, sleep apnea, and others.Type: GrantFiled: December 5, 2006Date of Patent: July 29, 2008Assignee: Develogen Aktiengesellschaft fur Entwicklungsbiologische ForshungInventors: Karsten Eulenberg, Gunter Bronner, Thomas Ciossek, Thomas Hader, Arnd Steuernagel
-
Publication number: 20080107639Abstract: The present invention discloses novel uses for energy homeostasis regulating proteins and polynucleotides encoding this in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders.Type: ApplicationFiled: January 19, 2005Publication date: May 8, 2008Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventor: Daria Onichtchouk
-
Publication number: 20070110728Abstract: The present invention relates generally to methods for preventing and/or treating pancreatic disorders, particularly those related to diabetes, by administering a DG119-1 product or a DG119-1 agonist and/or an antagonist To a DG 119-2 product.Type: ApplicationFiled: November 29, 2004Publication date: May 17, 2007Applicant: DEVELOGEN AKTIENGESELLSCHAFTInventors: Matthias Austen, Daria Onichtchouk, Thomas Siegmund, Kristin Aduroja, Bettina Rudolph, Friedrich Harder
-
Publication number: 20070107073Abstract: The present invention discloses proteins secreted by the developing pancreas, and polynucleotides, which identify and encode these proteins. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of pancreatic diseases (e.g. diabetes), obesity, and/or metabolic syndrome.Type: ApplicationFiled: November 19, 2004Publication date: May 10, 2007Applicant: DeveloGen AktiengesellschaftInventor: Daria Onichtchouk
-
Patent number: 7211563Abstract: The present invention discloses three novel proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to vectors, host cells, antibodies, and recombinant methods for producing the polypeptides and polynucleotides of the invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of diseases and disorders related to body-weight regulation, for example, but not limited to, metabolic diseases such as obesity, as well as related disorders such as adipositas, eating disorders, wasting syndromes (cachexia), pancreatic dysfunctions (such as diabetes mellitus), hypertension, pancreatic dysfunctions, arteriosclerosis, coronary artery disease (CAD), coronary heart disease, hypercholesterolemia, dyslipidemia, osteoarthritis, gallstones, cancer, e.g. cancers of the reproductive organs, sleep apnea, and others.Type: GrantFiled: March 28, 2002Date of Patent: May 1, 2007Assignee: Develogen Aktiengesellschaft fur Entwicklungsbiologische ForschungInventors: Karsten Eulenberg, Günter Brönner, Thomas Ciossek, Thomas Häder, Arnd Steuernagel
-
Publication number: 20060153806Abstract: The present invention discloses novel uses for energy homeostasis regulating proteins and polynucleotides encoding these in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders.Type: ApplicationFiled: December 16, 2003Publication date: July 13, 2006Applicant: DeveloGen Aktiengesellschaft fuer entwicklungsbiol ogical ForschungInventors: Martin Meise, Karsten Eulenberg, Andreas Molitor, Arnd Steuernagel, Tri Nguyen, Yvonne Katterle
-
Publication number: 20060135419Abstract: The prevent invention discloses PRL-1 homologous proteins regulating the energy homeostasis and the metabolism of triglycerides, and polynucleotides, which identify and encode the proteins disclosed in this invention. The invention also relates to the use of these sequences in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders.Type: ApplicationFiled: December 3, 2003Publication date: June 22, 2006Applicant: DeveloGen Aktiengesellschaft fuer entwick- lungsbiologische ForschungInventors: f Meise, Karsten Eulenberg, Tri Nguyen, Theodoros Tsetsenis
-
Publication number: 20050233956Abstract: The present invention discloses novel uses for energy homeostasis regulating proteins and polynucleotides encoding these in the diagnosis, study, prevention, and treatment of metabolic diseases and disorders.Type: ApplicationFiled: May 2, 2003Publication date: October 20, 2005Applicant: DeveloGen Aktiengesellschaft Fur Entwicklungsbiologische ForschungInventors: Karsten Eulenberg, Steuernagel Arnd, Hader Thomas, Meise Martin, Bronner Gunter